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Abstract
Targeted inhibition of the molecular chaperone heat shock protein 90 (Hsp90) results in the simultaneous blockade of multiple oncogenic signaling pathways and has thus emerged as an attractive strategy for the development of novel cancer therapeutics. Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 currently in clinical trials for a number of human cancers. Here we show that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematological tumor cell lines, including those that express mutated kinases that confer resistance to small molecule tyrosine kinase inhibitors (TKIs). Ganetespib treatment rapidly induced the degradation of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times. In vivo, ganetespib demonstrated potent antitumor efficacy in solid and hematological xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions. Of note, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis. Importantly, ganetespib showed no evidence of cardiac or liver toxicity. Taken together, this preclinical activity profile suggests that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first-and second-generation Hsp90 inhibitors.
Introduction
Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the post-translational folding, stability and function of its protein substrates ("client" proteins), many of which play critical roles in cell growth, differentiation and survival (1, 2) . As with other physiological processes that become co-opted by tumor cells, it is now clear that the chaperoning functions of Hsp90 can become subverted during tumorigenesis to facilitate malignant progression (1) . The Hsp90 machinery serves as a biochemical buffer for a number of oncogenic signaling proteins causally implicated in a variety of tumors (3, 4) . Often, these oncoproteins are expressed as mutant forms that are particularly reliant on Hsp90 for stability and function (5, 6) . Cancer cells contain elevated levels of the active form of the Hsp90 complex relative to normal cells, and have been shown to be selectively sensitive to Hsp90 inhibition (7, 8) . Moreover, a unique characteristic of targeting Hsp90 is that inhibition results in the combinatorial blockade of multiple signal transduction cascades, thereby potentially bypassing pathway redundancies often found in cancer cells (9) (10) (11) .
Thus, Hsp90 represents an attractive molecular target for the development of novel cancer therapeutics (4, 11, 12) .
The first class of Hsp90 inhibitors to be characterized were the benzoquinone ansamycins, including geldanamycin (GA) and its derivatives 17-allylamino-17-demethoxygeldanamycin (17-AAG), and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (13) . However the clinical progression of this group has been hampered due to several drawbacks including poor solubility, formulation problems, potential multidrug efflux, and hepatotoxicity (13, 14) . In addition, as single agents these inhibitors have only shown modest efficacies in the clinical setting (15, 16) , suggesting that they may be most effective as combination therapies. In an effort to overcome these limitations, several second generation synthetic Hsp90 inhibitors representing multiple drug classes are currently under development (17) (18) (19) (20) (21) (22) (23) 68.4% water). In the NCI-H1395 model, studies were conducted at the highest non-severely toxic doses of 150 mg/kg weekly; in the MV4-11 model, animals were treated with ganetespib at 100
and 125 mg/kg weekly; in the MKN45 model, animals were treated with ganetespib at 50 mg/kg 3 times a week. Tumor growth inhibition was determined as described previously (24) .
Microregional activity of ganetespib in NCI-H1975 xenografts
NCI-H1975 tumor xenograft implanted SCID mice were treated with 125 mg/kg ganetespib for 6-72 h. At the end of the experiment mice were administered BrdUrd and pimonidazole to label S phase cells and hypoxic tumor regions and then 5 min prior to excision mice were administered and stained with hematoxylin-eosin for routine histology evaluation.
Langendorff assay
Briefly, hearts from male New Zealand white rabbits were used to measure the physiological variables PQ, QRS, RR, QT, and dLVP/dt following perfusion with escalating doses of ganetespib 
Results
Ganetespib binds to the N-terminal ATP binding site in Hsp90
Ganetespib is a novel resorcinolic triazolone compound that is structurally distinct to the firstgeneration ansamycin Hsp90 inhibitors. The chemical structure is shown in Fig. 1A . With a molecular weight of 364.4, ganetespib is considerably smaller than the ansamycin class, and most of the newer, second generation Hsp90 inhibitors. Ganetespib is relatively hydrophobic, with a cLogP value of 3.3. Ganetespib exhibits competitive binding for the ATP pocket at the Nterminus of Hsp90. There are reports that the N-terminus can be crystallized in a number of conformations including an 'open' or 'closed' conformation in reference to the position of the ATP binding pocket lid (25) . We have obtained the co-crystal structure of ganetespib bound to the 'closed' conformation of the Hsp90 N-terminus (Fig. 1B) , however we anticipate that ganetespib can also access the ATP pocket in the 'open' conformation based on computational analysis (data not shown).
The X-ray co-crystal structure of ganetespib bound to Hsp90 ( Table 1 ). Of note, ganetespib retained potency against cell lines expressing mutated kinases that confer resistance to kinase inhibitors currently in clinical practice.
Ganetespib induces cell cycle arrest and apoptosis
Cell cycle analysis showed that ganetespib induced marked accumulation in the G 2 /M phase within 24 h in NCI-H1975 cells, with a concomitant loss of S phase ( Supplementary Fig. 1 ). The viable cell population remained blocked for at least 72 h; however, over this period, the percentage of apoptotic cells increased. To confirm this, cells were exposed to increasing concentrations of ganetespib for 6 to 72 h. Apoptosis was measured using activated caspase 3/7 levels and compared to cell viability ( Fig. 2A) . No effects were seen 6 h after treatment. However, the marked loss of viability following exposure to ganetespib observed 24-48 h post-treatment correlated with increased apoptotic induction. These results suggest that ganetespib-induced cytoxicity is mediated by an irreversible commitment to apoptosis, which is likely subsequent to growth arrest and effects on the cell cycle (24). 
Ganetespib exhibits sustained activity with short exposure times
We then investigated the exposure time of ganetespib required to induce cytotoxic responses in vitro using the NCI-H1975 and HCC827 NSCLC lines. Cells were exposed to ganetespib for the indicated times (5 min, 15 min, 60 min and 24 h), washed to remove the drug, and then grown in standard medium until cell viability was measured at 72 h (Fig. 2B) . Unexpectedly, exposure to ganetespib for only 60 min resulted in cytotoxicity IC 50 values of 510 nM and 800 nM for NCI-H1975 and HCC827 cells, respectively (Supplementary Table 2 ). Remarkably, a 5 min exposure to ganetespib in NCI-H1975 cells still resulted in an IC 50 value < 1 μM, a plasma concentration that is achievable in vivo. These findings indicated that cell viability was quickly affected by ganetespib treatment, and suggest that even brief drug exposure may be sufficient to affect tumor growth.
Ganetespib displays potent activity against drug-resistant tumor phenotypes in vitro
In NSCLC activating mutations in EGFR can drive tumorigenesis and confer sensitivity to tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib (26) . To examine whether ganetespib could overcome the resistant phenotype in NSCLC cells, we compared the activity of ganetespib and erlotinib ( Supplementary Fig. 2 ) using the NCI-H1975 cell line, which expresses a mutationally activated and erlotinib-resistant EGFR L858R/T790M mutation, and erlotinib-sensitive HCC827 cells, which express EGFR Del E746_A750 (Fig. 3A) . As expected, erlotinib treatment resulted in dosedependent cytotoxicity in HCC827 cells, but had no effect on NCI-H1975 cells. In contrast, ganetespib exhibited full potency against both cell lines, irrespective of EGFR mutational status.
Resistance to EGFR inhibitors may also emerge through alternative oncogenic mechanisms.
Hepatocyte growth factor (HGF), a ligand of the c-MET oncoprotein, can induce TKI resistance in lung tumors with EGFR-activating mutations by independently activating and restoring PI3K/AKT signaling via phosphorylation of c-MET (27, 28) . Given that EGFR, c-MET and AKT are all Hsp90 client proteins, we therefore determined whether ganetespib was active against c-MET-induced TKI-resistant cells. HCC827 cells were seeded in the presence or absence of HGF (50 ng/ml) and 24 h later were dosed with ganetespib or erlotinib. Cell viability was assessed 72 h after drug addition (Fig. 3B) . Both ganetespib and erlotinib were highly potent in non-stimulated HCC827 cells, with IC 50 values of approximately 10 nM. Importantly, while HGF-treated cells did not respond to erlotinib, ganetespib retained its potency in the presence of the growth factor. Similar results were observed in HCC827 cells selected for MET amplification (data not shown)
To examine modulation of MET-driven AKT signaling by ganetespib, HCC827 cells seeded with or without HGF for 24 h were treated with ganetespib or erlotinib at either 10 or 100 nM doses (which represent the IC 50 and IC 100 drug concentrations, respectively). Cells were harvested at 24 h and levels of MET, EGFR, and their relevant effectors were examined by Western blot (Fig.   3C ). Ganetespib treatment promoted the down-regulation of MET, EGFR and AKT protein levels in both the absence and presence of HGF, resulting in the complete loss of AKT and ERK activity. Erlotinib exposure was capable of inactivating AKT and ERK in the absence of HGF, but was ineffective in the presence of the growth factor.
Ganetespib exhibits potent in vivo activity in both solid and hematological xenograft models
To determine whether the effects of ganetespib in vitro translate to antitumor efficacy in vivo, the activity of ganetespib was evaluated using a variety of doses and schedules in a series of xenograft models. Initially, SCID mice bearing NCI-H1395 NSCLC xenografts were dosed intravenously (i.v.) with ganetespib on a weekly schedule at its highest non-severely toxic dose (HNSTD) of 150 mg/kg (Fig. 4A) . NCI-H1395 tumor regression was induced by ganetespib with a T/C value of -49% compared with the control group. Importantly, this regimen was well tolerated with minimal loss of body weight observed during the course of treatment (Fig. 4B) . 
MV4-11 acute myeloid leukemia (AML) cells express the Hsp90 client protein FLT3, an oncogenic driver and the most common genetic alteration associated with AML (29) . This cell line is highly sensitive to ganetespib in vitro (IC 50 value of 4 nM, Supplementary Table 1) . Ganetespib was administered i.v. to MV4-11 tumor-bearing SCID mice once weekly at 100 mg/kg and 125 mg/kg.
As shown in Fig. 4C , these two treatment regimens resulted in significant tumor regression (85% and 94%, respectively). Moreover, tumors were undetectable in 37.5% of ganetespib treated animals at the end of the 3 week dosing period.
Amplification of the c-MET receptor tyrosine kinase occurs in approximately 20% of gastric carcinomas (30) . We therefore used the human c-MET amplified MKN45 gastric carcinoma cell line as an additional xenograft model of oncogene addiction to examine the antitumor activity of ganetespib (Fig. 4D) . Ganetespib treatment was again highly efficacious in this study, with a 50 mg/kg dose 3 times per week resulting in 92% inhibition of tumor growth.
Ganetespib penetrates hypoxic regions of tumors in vivo
To evaluate tumor penetration, the microregional activity of ganetespib was assessed in NCI-H1975 tumor xenografts. Immunohistochemical markers of proliferation (bromodeoxyuridine), apoptosis (TUNEL) and hypoxia (HIF-1α) in tumors were mapped in relation to distance from the nearest CD31 + endothelial cells (Fig. 5) . A single dose of ganetespib at 125mg/kg dramatically reduced cellular proliferation throughout the tumors, with the maximal effect occurring 24 h following treatment (Fig. 5A ). Further, a concomitant induction of tumor cell apoptosis occurred within 24 h (Fig. 5B) . Moreover, at 6 h, apoptosis was preferentially induced near vessels and then became uniformly induced throughout the tissue by the 48 h time point (data not shown).
Increased HIF-1α staining as a function of distance confirmed the hypoxic gradient that existed within the tumors and, importantly, this Hsp90 client protein was potently suppressed in vivo following treatment with ganetespib (Fig. 5C ). These results provide strong evidence that ganetespib efficiently distributed within the extravascular compartment, including the hypoxic 
Ganetespib exhibits a favorable safety profile
The hepatotoxicity profile of ganetespib was evaluated in male Sprague Dawley rats based on changes in the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Fig. 6A ). Animals were treated with repeated administration of ganetespib at 25, 50 and 75 mg/kg/d for 5 days, or 17-DMAG ( Supplementary Fig. 2 ) at 2, 4, and 6mg/kg/d for 4 days. No changes in the levels of either enzyme were observed in the ganetespib-treated animals, even at the highest dose of 75 mg/kg, which is higher than the efficacious dose range for this compound.
The 75 mg/kg dose represented the effective maximum tolerated dose in these animals, as extensive GI toxicity was observed following the 5 day treatment. In stark contrast, a dosedependent and marked elevation of ALT (293% -510%) and AST (149 % -296%) was seen with 17-DMAG treated rats, at doses 12.5 times lower than ganetespib. Histologic analysis (Fig. 6B) revealed that livers of animals treated with 17-DMAG at the lowest 2 mg/kg dose showed patchy and focal hepatocytic apoptosis with mild mononuclear cell infiltration. At the 6 mg/kg dose, the lesions were diffuse and severe, including larger areas of coagulative hepatocytic necrosis.
These injuries were primarily observed in the area near the central vein of the hepatic plate and are consistent with the elevated levels of liver enzymes. In accordance with the lack of enzymatic induction, there were no discernable morphologic changes in the hepatocytes of animals treated with ganetespib.
Cardiovascular effects of escalating doses ganetespib on electrophysiological (PQ, QRS, RR
and QTc) and mechanical (left ventricular developed pressure) properties were evaluated in isolated New Zealand white rabbit hearts. Ganetespib exerted no significant physiological effects other than a minimal reduction in AV conduction (lengthening PQ interval) and a minor reduction in heart rate (increased RR interval) over the concentrations 10 M when compared to baseline or vehicle (Fig. 6C) . Similarly, there was no change in the QRS duration after exposure to concentrations of ganetespib ranging from 10 -8 to 10 -6 M, when compared to baseline or vehicle; however an increase in the duration of the QRS was noted after exposure to the 10 -5 M concentration (Fig. 6C) . M, the highest concentration tested, ganetespib lengthened PQ interval and QRS duration, however this concentration was approximately 3000 fold higher than the unbound C max in the 125mg/kg dose in the NCI-H1975
tumor penetration studies ( Figure 5 ). Other cardiac electrophysiological parameters and mechanical properties, including left ventricular developed pressure, were not significantly altered following exposure to ganetespib, while expected physiological changes with the positive control quinidine were observed (data not shown). 
Discussion
In this study we provide the first preclinical characterization of ganetespib, a novel and potent inhibitor of Hsp90 that offers considerable promise as a new targeted cancer therapeutic.
Structurally, ganetespib is distinct to the first-generation ansamycin Hsp90 inhibitors, with a unique scaffold that is considerably smaller than these GA analogs. Hsp90 chaperone activity is associated with an ATP-driven conformational change within the N-terminal domain (31, 32) . Our data show that ganetespib is able to enter the ATP binding pocket in the so-called 'closed' (33) . This lack of restriction for binding to the Hsp90 ATP pocket may be one of the reasons that ganetespib demonstrates higher in vitro potency compared to the GA analogs. Also, our structural analysis has identified a series of additional hydrogen bond interactions due to the presence of the triazolone moiety that predict for superior binding affinities between ganetespib and Hsp90, further distinguishing this compound from the GA class.
Human cancers are typically characterized by a variety of genetic alterations that collectively contribute to the transformed state, however a subset are now believed to be dependent on single, definable oncogenic pathways for their genesis, proliferation and/or survival. This phenomenon is known as oncogene addiction (34) (38) . The most important observation, however, was that the physicochemical properties of the compound resulted in extensive penetration and distribution of ganetespib throughout tumors, including hypoxic regions distal to the nearest blood vessels. From a clinical perspective, the effectiveness of many anticancer agents can be compromised by limited drug distribution, as efficient penetration is necessary to reach the target population and in concentrations sufficient to exert a therapeutic effect (39) . In this regard, ganetespib treatment rapidly and dramatically reduced proliferation and induced apoptosis in xenograft tissues independent of the distance from the microvasculature. The capacity of ganetespib to penetrate the extravascular compartment of solid tumors combined with its extended tumor retention and cellular potency clearly predicts for maximal efficacy. Overall unfavorable safety profiles, including hepatotoxicity, have hampered the clinical application of the ansamycin class of Hsp90 inhibitors. There the chemical reactivity of the benzoquinone group appears accountable for the observed elevation of liver enzymes and associated liver toxicity in the clinical setting (4) . Consistent with the findings for other rationally designed second-generation inhibitors, ganetespib showed no evidence of liver toxicity in the preclinical assessment of changes in liver enzymes or histopathology. Cardiac toxicity is also potential risk factor for many classes of drugs, in part due to adverse effects on critical ion channels that regulate heart beat (37). Our cardiovascular analysis revealed that the two predominant effects attributable to exposure to ganetespib in the Langendorff assay were a slight dose-dependent lengthening of the PQ interval and a minor change in QRS duration at the 10 -5 M concentration. Moreover, the observation that the QTc interval did not lengthen is consistent with ganetespib having no effect on ventricular repolarization. Together with no significant alterations in other electrophysiological and mechanical parameters, ganetespib therefore exhibits a favorable cardiotoxic profile. Importantly, our safety studies were performed to maximally tolerated doses and no other adverse events were seen to suggest that ganetespib manifests any additional toxicities. Of note, ocular toxicities have recently emerged as an undesirable side-effect for the newer synthetic Hsp90 inhibitors (40) . To date, over 400 patients have been treated with ganetespib, and an absence of ocular toxicity is evident (<3%, W. Ying, unpublished observation). Currently a comprehensive profiling of ganetespib and other Hsp90 inhibitors for potential CNS or ocular toxicity risks is underway.
In summary, we have developed and characterized a unique small-molecule Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies both in vitro and in vivo. Importantly, ganetespib retained its potency against tumor phenotypes that confer drug resistance to agents currently in use in the clinic. In addition, ganetespib displays optimal pharmacological properties including high tumor penetration and a favorable safety profile that 
